REFERENCES
1. Lecaille F, Kaleta J, Brömme D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem Rev 2002;102:4459-88.
2. Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta 2012;1824:68-88.
3. Brix K, Dunkhorst A, Mayer K, Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008;90:194-207.
4. Kramer L, Turk D, Turk B. The future of cysteine cathepsins in disease management. Trends Pharmacol Sci 2017;38:873-98.
5. Lecaille F, Brömme D, Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie 2008;90:208-26.
6. Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 2009;18:585-600.
7. Novinec M, Lenarčič B. Cathepsin K: a unique collagenolytic cysteine peptidase. Biol Chem 2013;394:1163-79.
8. Qian D, He L, Zhang Q, et al. Cathepsin K: a versatile potential biomarker and therapeutic target for various cancers. Curr Oncol 2022;29:5963-87.
9. Rocho FR, Bonatto V, Lameiro RF, Lameira J, Leitão A, Montanari CA. A patent review on cathepsin K inhibitors to treat osteoporosis (2011-2021). Expert Opin Ther Pat 2022;32:561-73.
10. Verbovšek U, Van Noorden CJ, Lah TT. Complexity of cancer protease biology: cathepsin K expression and function in cancer progression. Semin Cancer Biol 2015;35:71-84.
12. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157-62.
13. Jaffer FA, Kim DE, Quinti L, et al. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 2007;115:2292-8.
14. Lecaille F, Weidauer E, Juliano MA, Brömme D, Lalmanach G. Probing cathepsin K activity with a selective substrate spanning its active site. Biochem J 2003;375:307-12.
15. Lemke C, Benýšek J, Brajtenbach D, et al. An activity-based probe for cathepsin K imaging with excellent potency and selectivity. J Med Chem 2021;64:13793-806.
16. Richard ET, Morinaga K, Zheng Y, et al. Design and synthesis of cathepsin-k-activated osteoadsorptive fluorogenic sentinel (OFS) probes for detecting early osteoclastic bone resorption in a multiple myeloma mouse model. Bioconjug Chem 2021;32:916-27.
17. Li Z, Hou WS, Brömme D. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Biochemistry 2000;39:529-36.
18. Li Z, Hou W-S, Escalante-Torres CR, et al. Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. J Biol Chem 2002;277:28669-28676.
19. Fonović M, Turk B. Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys Acta 2014;1840:2560-70.
20. Brisson L, Reshkin SJ, Goré J, Roger S. pH regulators in invadosomal functioning: proton delivery for matrix tasting. Eur J Cell Biol 2012;91:847-60.
21. Punturieri A, Filippov S, Allen E, et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med 2000;192:789-99.
22. Brömme D, Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler 1995;376:379-384.
23. Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Rünger TM. Expression and regulation of cathepsin K in skin fibroblasts. Exp Dermatol 2009;18:596-602.
24. Friedrichs B, Tepel C, Reinheckel T, et al. Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest 2003;111:1733-45.
25. Tepel C, Brömme D, Herzog V, Brix K. Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin. J Cell Sci 2000;113 Pt 24:4487-98.
26. Bühling F, Waldburg N, Reisenauer A, et al. Lysosomal cysteine proteases in the lung: role in protein processing and immunoregulation. Eur Respir J 2004;23:620-628.
27. Zhang D, Leung N, Weber E, Saftig P, Brömme D. The effect of cathepsin K deficiency on airway development and TGF-β1 degradation. Respir Res 2011;12:72.
29. Chen H, Wang J, Xiang MX, et al. Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction. Cardiovasc Res 2013;100:84-94.
30. Yue X, Piao L, Wang H, et al. Cathepsin K deficiency prevented kidney damage and dysfunction in response to 5/6 nephrectomy injury in mice with or without chronic stress. Hypertension 2022;79:1713-23.
31. Zhang X, Zhou Y, Yu X, et al. Differential roles of cysteinyl cathepsins in tgf-β signaling and tissue fibrosis. iScience 2019;19:607-22.
32. Lalmanach G, Saidi A, Marchand-Adam S, Lecaille F, Kasabova M. Cysteine cathepsins and cystatins: from ancillary tasks to prominent status in lung diseases. Biol Chem 2015;396:111-30.
33. Kasabova M, Joulin-Giet A, Lecaille F, et al. Regulation of TGF-β1-driven differentiation of human lung fibroblasts: emerging roles of cathepsin B and cystatin C. J Biol Chem 2014;289:16239-51.
34. Biasizzo M, Javoršek U, Vidak E, Zarić M, Turk B. Cysteine cathepsins: a long and winding road towards clinics. Mol Aspects Med 2022;88:101150.
35. Henriksen K, Thudium CS, Christiansen C, Karsdal MA. Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disorders. Expert Opin Ther Targets 2015;19:1575-84.
36. Wen X, Yi LZ, Liu F, Wei JH, Xue Y. The role of cathepsin K in oral and maxillofacial disorders. Oral Dis 2016;22:109-15.
37. Xue Y, Wang L, Xia D, et al. Dental abnormalities caused by novel compound heterozygous
38. Zhang Y, Ji D, Li L, Yang S, Zhang H, Duan X. ClC-7 Regulates the pattern and early development of craniofacial bone and tooth. Theranostics 2019;9:1387-400.
39. McClung MR, O'Donoghue ML, Papapoulos SE, et al. LOFT Investigators. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol 2019;7:899-911.
40. Panwar P, Law S, Jamroz A, et al. Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone. Br J Pharmacol 2018;175:902-23.
41. Panwar P, Xue L, Søe K, et al. An ectosteric inhibitor of cathepsin K inhibits bone resorption in ovariectomized mice. J Bone Miner Res 2017;32:2415-30.
42. Yang YS, Xie J, Chaugule S, et al. Bone-Targeting AAV-mediated gene silencing in osteoclasts for osteoporosis therapy. Mol Ther Methods Clin Dev 2020;17:922-35.
43. Cottin V, Archer F, Khouatra C, Lazor R, Cordier JF. Lymphangioléiomyomatose pulmonaireLymphangioleiomyomatosis. Presse Med 2010;39:116-25.
44. Johnson SR, Cordier JF, Lazor R, et al. Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010;35:14-26.
45. Harknett EC, Chang WY, Byrnes S, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM 2011;104:971-9.
46. Henske EP, McCormack FX. Lymphangioleiomyomatosis - a wolf in sheep’s clothing. J Clin Invest 2012;122:3807-16.
47. Taveira-DaSilva AM, Moss J. Epidemiology, pathogenesis and diagnosis of lymphangioleiomyomatosis. Expert Opin Orphan Drugs 2016;4:369-78.
48. Ruiz de Garibay G, Herranz C, Llorente A, et al. Lymphangioleiomyomatosis biomarkers linked to lung metastatic potential and cell stemness. PLoS One 2015;10:e0132546.
49. Gown AM, Vogel AM, Hoak D, et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
50. Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 1999;21:327-36.
51. Young L, Lee HS, Inoue Y, et al. MILES Trial Group. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013;1:445-52.
52. Gupta N, Henske EP. Pulmonary manifestations in tuberous sclerosis complex. Am J Med Genet C Semin Med Genet 2018;178:326-37.
53. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998;62:810-5.
54. Yu J, Henske EP. mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the “perfect storm” of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol 2010;8:43-9.
55. McCarthy C, Gupta N, Johnson SR, Yu JJ, McCormack FX. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med 2021;9:1313-27.
56. Harari S, Spagnolo P, Cocconcelli E, Luisi F, Cottin V. Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis. Curr Opin Pulm Med 2018;24:469-76.
57. Courtwright AM, Goldberg HJ, Henske EP, El-Chemaly S. The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis. Eur Respir Rev 2017;26:160004.
58. Moir LM. Lymphangioleiomyomatosis: Current understanding and potential treatments. Pharmacol Ther 2016;158:114-24.
59. Chilosi M, Pea M, Martignoni G, et al. Cathepsin-k expression in pulmonary lymphangioleiomyomatosis. Mod Pathol 2009;22:161-166.
60. Dongre A, Clements D, Fisher AJ, Johnson SR. Cathepsin K in lymphangioleiomyomatosis: LAM cell-fibroblast interactions enhance protease activity by extracellular acidification. Am J Pathol 2017;187:1750-62.
61. Caliò A, Brunelli M, Gobbo S, et al. Cathepsin K: a novel diagnostic and predictive biomarker for renal tumors. Cancers (Basel) 2021;13:2441.
62. Rolim I, Makupson M, Lovrenski A, Farver C. Cathepsin K is superior to HMB45 for the diagnosis of pulmonary lymphangioleiomyomatosis. Appl Immunohistochem Mol Morphol 2022;30:108-12.
63. Westergren-Thorsson G, Hedström U, Nybom A, et al. Increased deposition of glycosaminoglycans and altered structure of heparan sulfate in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2017;83:27-38.
64. Chazeirat T, Denamur S, Bojarski KK, et al. The abnormal accumulation of heparan sulfate in patients with mucopolysaccharidosis prevents the elastolytic activity of cathepsin V. Carbohydr Polym 2021;253:117261.
65. Kant S, Kumar A, Singh SM. Bicarbonate transport inhibitor SITS modulates pH homeostasis triggering apoptosis of Dalton’s lymphoma: implication of novel molecular mechanisms. Mol Cell Biochem 2014;397:167-78.
66. Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896-902.
67. Miller S, Stewart ID, Clements D, Soomro I, Babaei-Jadidi R, Johnson SR. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response. J Pathol Clin Res 2020;6:215-26.
68. Taveira-Dasilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Bone mineral density in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2005;171:61-7.
69. Iakymenko OA, Delma KS, Jorda M, Kryvenko ON. Cathepsin K (Clone EPR19992) demonstrates uniformly positive immunoreactivity in renal oncocytoma, chromophobe renal cell carcinoma, and distal tubules. Int J Surg Pathol 2021;29:600-5.
70. Seo SU, Woo SM, Kim MW, et al. Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization. Redox Biol 2020;30:101422.
